Early inflammatory markers as prognostic indicators following allogeneic stem cell transplantation

Publication
Article

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation. This study seeks to enhance early prediction of patient outcomes through the monitoring of 92 proteins immediately after transplantation and 2 weeks post-transplantation.

The study found that patients who later developed acute graft versus host disease exhibited lower levels of IL18-R1, LIF-R, and IL22-RA1. Conversely, those who experienced chronic GvHD displayed lower levels of CD244, TSLP, IL15-RA, and IL-33. Higher levels of seven inflammatory proteins—CD244, LIF-R, FGF21, IL10-RB, HGF, CD40, and TNFRSF9—were linked to an increased risk of disease relapse. This underscores the importance of dynamic monitoring of inflammatory responses to better predict and potentially mitigate post-transplant complications.

These findings emphasize the potential role of specific proteins and their receptors in alloreactive immunity and suggest a link between baseline inflammatory profiles and treatment outcomes. The trajectory of change in protein concentrations provides a strong indication of the risk of GvHD or relapse, indicating a strategic approach to patient monitoring that could lead to personalized care. Despite its limitations, such as the need for validation in larger cohorts, this study marks a significant step toward the utilization of early post-transplant biomarkers for predicting clinical outcomes.

Reference

Verma K, Croft W, Greenwood D, et al. Early inflammatory markers as prognostic indicators following allogeneic stem cell transplantation. Front Immunol. 2024;14:1332777. Published 2024 Jan 3.

https://doi.org/10.3389/fimmu.2023.1332777

Recent Videos
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Related Content